Crossmark

Humanized anti CD-20 as an alternative in chronic management of relapsing thrombotic thrombocytopenic microangiopathy resistant to rituximab due to anti chimeric antibody

Crossref DOI link: https://doi.org/10.1007/s12185-020-03020-7

Published Online: 2020-10-16

Published Print: 2021-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ahmadpoor, Pedram

Aglae, Cedric

Garo, Florian

Cariou, Sylvain

Renaud, Sophie

Reboul, Pascal

Moranne, Olivier https://orcid.org/0000-0002-3127-1415
License Information

Text and Data Mining valid from 2020-10-16

Version of Record valid from 2020-10-16
More Information

Article History

Received: 26 May 2020

Revised: 7 September 2020

Accepted: 1 October 2020

First Online: 16 October 2020

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below